Jennison Associates’s Protagonist Therapeutics PTGX Stock Holding History

Jennison Associates’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$113M	Buy	1,072,011 +740,847	+224%	+$65.6M	0.08%	118
2025 Q4	$28.9M	Buy	+331,164	New	+$27.1M	0.02%	284
2025 Q2	–	Sell	-18,317	Closed	-$886K	–	625
2025 Q1	$886K	Buy	+18,317	New	+$768K	﹤0.01%	490
2023 Q2	–	Sell	-428,938	Closed	-$9.87M	–	615
2023 Q1	$9.87M	Buy	+428,938	New	+$7.2M	0.01%	392
2018 Q4	–	Sell	-349,697	Closed	-$3.6M	–	703
2018 Q3	$3.6M	Buy	+349,697	New	+$3.01M	﹤0.01%	506
2018 Q1	–	Sell	-100,000	Closed	-$2.08M	–	694
2017 Q4	$2.08M	Buy	+100,000	New	+$1.77M	﹤0.01%	528

Other funds holding PTGX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Jennison Associates's PTGX Position: Q1 2026 in Review

Jennison Associates increased its Protagonist Therapeutics (PTGX) stake by 224% in Q1 2026, buying an estimated $65.6M and bringing the position to 1,072,011 shares worth $113M. The position accounts for 0.08% of the portfolio, ranked #118.

Jennison Associates first reported a position in PTGX in Q4 2017 and has held it in 6 quarters since. 317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

Jennison Associates held 1,072,011 shares of Protagonist Therapeutics worth $113M as of Q1 2026.
Jennison Associates bought 740,847 Protagonist Therapeutics shares in Q1 2026, an estimated $65.6M.
Protagonist Therapeutics made up 0.08% of Jennison Associates's portfolio in Q1 2026, its #118 holding.
Jennison Associates first reported a position in Protagonist Therapeutics in Q4 2017 and has held it in 6 quarters since.
317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Jennison Associates's 13F filing for Q1 2026, filed 6 May 2026.